A carregar...
Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China
BACKGROUND: Pegylated interferon (PEG-IFN) alfa-2b is recommended for chronic hepatitis B (CHB). We aimed to investigate the sustainability of off-treatment responses among Chinese HBeAg-positive CHB patients treated with PEG-IFN alfa-2b from a randomized trial. METHODS: Eligible Chinese patients (n...
Na minha lista:
Publicado no: | BMC Gastroenterol |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
BioMed Central
2019
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6498535/ https://ncbi.nlm.nih.gov/pubmed/31046700 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12876-019-0981-5 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|